Low-dose recombinant IL-2 induces psychological changes: Monitoring by Minnesota Multiphasic Personality Inventory (MMPI)

Anticancer Research

Volumn 22, Issue 2 A, 2002, Pages 727-732

  Pizzi, Claudia ^a   Caraglia, Michele ^a   Cianciulli, Maria ^a   Fabbrocini, Antonietta ^a   Libroia, Anna ^a   Matano, Elide ^a   Contegiacomo, Alma ^a   Del Prete, Salvatore ^a   Abbruzzese, Alberto ^a   Martignetti, Angelo ^a   Tagliaferri, Pierosandro ^a   Bianco, Angelo Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

MMPI; Psychological monitoring; rIL 2

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; DEPRESSION; DRUG EXPOSURE; FEMALE; HUMAN; HYSTERIA; IMMUNOMODULATION; KIDNEY CARCINOMA; MALE; MELANOMA; MENTAL DISEASE; MINNESOTA MULTIPHASIC PERSONALITY INVENTORY; PRIORITY JOURNAL; PSYCHOPATHY; SCHIZOPHRENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; MMPI; PERSONALITY DISORDERS; RECOMBINANT PROTEINS;

EID: 0036248823     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients
2. Natural history and therapy of metastatic renal cell carcinoma: Role of interleukin-2
3. Home therapy with recombinant interleukin-2 and interferon γ-2b in advanced human malignancies
4. A comparison of 2 modes of administration of recombinant interleukin-2: Continuous intravenous infusion alone versus subcutaneous administration plus interferon-alpha in patients with advanced renal cell carcinoma
5. Daily subcutaneous injection of low dose interleukin-2 expands natural killer cells in vivo without significant toxicity
6. Recombinant human interleukin-2, recombinant human Interferon alpha-2a, or both in metastatic renal cell carcinoma
7. Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration
8. Trial-related quality of life: Using quality of life assessment to distinguish among cancer therapies
9. The immune response evokes changes in brain noradrenergic neurones
10. Interleukin-2 as a neuroregulatory cytokine
11. Central nervous system toxicity of interferon
12. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer
13. Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status
14. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells
15. Interleukin-2 toxicity
16. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration
17. Psychological side effects induced by interleukin-2/alpha interferon treatment
18. The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: A controlled clinical trial using computerised assessments
19. The psychological and psychiatric effects of rIL-2 therapy: A controlled clinical trial
20. Computerised clinical and personality assessment using the MMPI
21. Psychoneuroimmunology: Interactions between the nervous system and the immune system
22. Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency
23. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone